Cogent Biosciences, Inc.
NASDAQ: COGT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew R. Robbins
- Employees
- 205
- Headquarters
- Waltham, United States
- IPO year
- 2018
- Market cap
- $5.9B
- Website
- https://www.cogentbio.com
Loading COGT…
Loading profile data…Frequently asked questions about COGT
What does Cogent Biosciences, Inc. (COGT) do?
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 1...
Where does COGT trade?
Cogent Biosciences, Inc. (COGT) trades on the NASDAQ Global Select.
What sector is COGT in?
Cogent Biosciences, Inc. (COGT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cogent Biosciences, Inc.?
Andrew R. Robbins is the chief executive officer of Cogent Biosciences, Inc. (COGT).
Where is Cogent Biosciences, Inc. headquartered?
Cogent Biosciences, Inc. is headquartered in United States.
Does COGT pay a dividend?
Cogent Biosciences, Inc. (COGT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did COGT go public?
Cogent Biosciences, Inc. (COGT) completed its initial public offering in 2018.